Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2026
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2026 | $1.1B | $331M | $190M | $246M | 10.1% | -4.3% | -11.3% |
| 2025 | $1.1B | $362M | $215M | $243M | 11.7% | 1.1% | 2.5% |
| 2024 | $1.1B | $374M | $209M | $239M | 12.6% | -0.2% | -354.3% |
| 2023 | $1.1B | $8M | $-82M | $222M | -5.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,127.72 | 1,125.36 | 1,137.76 | 1,088.70 |
| Operating Revenue | - | 1,127.62 | 1,125.05 | 1,136.58 | 1,084.74 |
| Cost Of Revenue | - | 502.43 | 500.91 | 503.30 | 493.13 |
| Gross Profit | - | 625.29 | 624.45 | 634.46 | 595.58 |
| Operating Expense | - | 277.49 | 282.02 | 285.22 | 286.17 |
| Selling General And Administration | - | 252.42 | 259.47 | 263.93 | 265.23 |
| Total Expenses | - | 779.92 | 782.93 | 788.52 | 779.30 |
| Operating Income | - | 347.80 | 342.43 | 349.24 | 309.41 |
| Total Operating Income As Reported | - | -22.42 | 342.43 | 336.78 | 309.41 |
| EBITDA | - | 7.87 | 373.86 | 361.99 | 331.11 |
| Normalized EBITDA | - | 378.09 | 373.86 | 374.46 | 331.11 |
| EBIT | - | -24.75 | 343.18 | 331.82 | 299.83 |
| Interest Expense | - | 69.16 | 67.16 | 47.63 | 42.34 |
| Net Interest Income | - | -69.16 | -67.16 | -47.63 | -42.34 |
| Other Non Operating Income Expenses | - | -2.34 | 0.76 | -4.95 | -9.57 |
| Other Income Expense | - | -372.55 | 0.76 | -17.42 | -9.57 |
| Interest Expense Non Operating | - | 69.16 | 67.16 | 47.63 | 42.34 |
| Net Non Operating Interest Income Expense | - | -69.16 | -67.16 | -47.63 | -42.34 |
| Pretax Income | - | -93.92 | 276.02 | 284.19 | 257.50 |
| Tax Provision | - | -11.61 | 66.69 | 69.58 | 67.19 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -45.76 | 0 | -3.05 | 0 |
| Net Income Continuous Operations | - | -82.31 | 209.34 | 214.60 | 190.30 |
| Net Income From Continuing And Discontinued Operation | - | -82.31 | 209.34 | 214.60 | 190.30 |
| Net Income From Continuing Operation Net Minority Interest | - | -82.31 | 209.34 | 214.60 | 190.30 |
| Net Income | - | -82.31 | 209.34 | 214.60 | 190.30 |
| Net Income Common Stockholders | - | -82.31 | 209.34 | 214.60 | 190.30 |
| Net Income Including Noncontrolling Interests | - | -82.31 | 209.34 | 214.60 | 190.30 |
| Normalized Income | - | 242.15 | 209.34 | 224.02 | 190.30 |
| Diluted NI Availto Com Stockholders | - | -82.31 | 209.34 | 214.60 | 190.30 |
| Basic Average Shares | - | 49.89 | 49.76 | 49.70 | 48.46 |
| Diluted Average Shares | - | 49.89 | 50.18 | 50.08 | 48.72 |
| Reconciled Depreciation | - | 32.62 | 30.68 | 30.17 | 31.27 |
| Reconciled Cost Of Revenue | - | 494.88 | 492.79 | 494.42 | 482.79 |
| Total Unusual Items | - | -370.22 | 0 | -12.47 | 0 |
| Total Unusual Items Excluding Goodwill | - | -370.22 | 0 | -12.47 | 0 |
| Special Income Charges | - | -370.22 | 0 | -12.47 | 0 |
| Other Special Charges | 2.12 | - | - | - | - |
| Impairment Of Capital Assets | - | 370.22 | 0 | 12.47 | 0 |
| Depreciation Amortization Depletion Income Statement | - | 25.08 | 22.55 | 21.29 | 20.94 |
| Depreciation And Amortization In Income Statement | - | 25.08 | 22.55 | 21.29 | 20.94 |
| General And Administrative Expense | - | 107.35 | 106.15 | 108.21 | 116.45 |
| Other Gand A | - | 107.35 | 106.15 | 108.21 | 116.45 |
| Selling And Marketing Expense | - | 145.06 | 153.32 | 155.72 | 148.78 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Prestige Consumer Healthcare Inc.this co. | PBH | $2.2B | 11.31β premium | 1.14 | 10.1% | 9.47 |
| Supernus Pharmaceuticals, Inc. | SUPN | $2.6B | -67.30 | 2.44 | -3.6% | 58.94 |
| TransMedics Group, Inc. | TMDX | $2.5B | 12.96 | 5.21 | 40.2% | 16.82 |
| Acadia Healthcare Company, Inc. | ACHC | $2.3B | -2.10 | 1.19 | -56.6% | -6.55 |
| LeMaitre Vascular, Inc. |
| 2022 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| LMAT |
| $2.1B |
| 37.03 |
| 5.43 |
| 14.7% |
| 25.28 |
| Select Medical Holdings Corporation | SEM | $2.0B | 13.99 | 1.20 | 8.6% | 9.20 |
| Neogen Corporation | NEOG | $2.0B | -1.82 | 0.96 | -52.7% | -2.94 |
| ADMA Biologics, Inc. | ADMA | $1.8B | 12.59 | 3.87 | 30.8% | 9.31 |
| Sarepta Therapeutics, Inc. | SRPT | $1.8B | -2.47 | 1.54 | -62.5% | -3.22 |
| Peer Median | - | 5.39 | 1.99 | 2.5% | 9.26 | |